De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu dopisy, práce podpořená grantem
Grantová podpora
00023736
Ministerstvo Zdravotnictví Ceské Republiky
00669806
Ministerstvo Zdravotnictví Ceské Republiky
LX22NPO5102
Ministerstvo Školství, Mládeže a Tělovýchovy
MUNI/A/1558/2023
Ministerstvo Školství, Mládeže a Tělovýchovy
PubMed
38317312
DOI
10.1002/ajh.27229
Knihovny.cz E-zdroje
- MeSH
- blastická krize farmakoterapie MeSH
- chronická myeloidní leukemie * farmakoterapie MeSH
- inhibitory proteinkinas terapeutické užití MeSH
- inhibitory tyrosinkinasy * MeSH
- lidé MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- dopisy MeSH
- práce podpořená grantem MeSH
- Názvy látek
- inhibitory proteinkinas MeSH
- inhibitory tyrosinkinasy * MeSH
Overall survival of patients classified according to the European LeukemiaNet 2020 classification. Chronic phase (CP), accelerated phase (AP), blast crisis (BC), low risk (LR), intermediate risk (IR), high risk (HR).
1st Internal Dpt General University Hospital Prague Prague Czech Republic
Central European Institute of Technology Masaryk University Brno Czech Republic
Dpt of Hemato oncology University Hospital Olomouc and Palacky University Olomouc Czech Republic
Dpt of Hemato oncology University Hospital Pilsen and Charles University Pilsen Czech Republic
Dpt of Hematooncology Faculty of Medicine University of Ostrava Ostrava Czech Republic
Dpt of Hematooncology University Hospital Ostrava Ostrava Czech Republic
Institute of Biostatistics and Analyses Brno Czech Republic
Institute of Hematology and Blood Transfusion Prague Czech Republic
Zobrazit více v PubMed
Foley TH, Bennett JM, Carbone PP. Combination chemotherapy in accelerated phase of chronic granulocytic leukemia. Arch Intern Med. 1969;123:166-170.
Kantarjian HM, Dixon D, Keating MJ, et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer. 1988;61:1441-1446.
Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391-2405.
Arber DA, Orazi A, Hasserjian R, et al. International consensus classification of myeloid neoplasms and acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200-1228.
Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966-984.
Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of Haematolymphoid Tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36:1703-1719.
Kantarjian HM, Tefferi A. Classification of accelerated phase chronic myeloid leukemia in the era of the BCR::ABL1 tyrosine kinase inhibitors: a work in progress. Am J Hematol. 2023;98:1350-1353.
Pfirrmann M, Baccarani M, Saussele S, et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia. 2015;30:48-56.
